GLP1R and obesity due to melanocortin 4 receptor deficiency: GLP-1 agonists are FDA-approved drugs used in the treatment of type 2 diabetes mellitus and obesity as they increase insulin release, decrease glucagon production, enhance proliferation of pancreatic beta cells, and delay gastric emptying (Collins and Costello 2024).